AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25591130 — intervention group
Group type: COMPARATOR
Intervention: Leg strengthening exercise program
Number of subjects: 72
Study 23340530 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency (PRF) at 42° C for 120 seconds, applied twice, once a week for 3 weeks.
Number of subjects: 96
Study 23340530 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency (PRF) group
Number of subjects: 96
Study 23340530 — intervention group
Group type: COMPARATOR
Intervention: Sham group (no radiofrequency energy output)
Number of subjects: 96
Study 21907499 — intervention group
Group type: EXPERIMENTAL
Intervention: Involuntary medication treatment
Number of subjects: 0
Study 19401368 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 0
Study 17127797 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol dose 1-2 ml (Group A)
Number of subjects: 54
Study 17127797 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol dose >2 ml (Group B)
Number of subjects: 54
Study 15262845 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus 3 mg/d
Number of subjects: 136
Study 15262845 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus 5 mg/d
Number of subjects: 136
Study 15262845 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 136
Study 15262845 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 136
Study 10903230 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive investigation (Group 1)
Number of subjects: 76
Study 10903230 — intervention group
Group type: COMPARATOR
Intervention: Invasive investigation (Group 2)
Number of subjects: 76
Study 9076457 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C instillation (20-week protocol)
Number of subjects: 419
Study 9076457 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin instillation (3-year protocol)
Number of subjects: 419
Study 8261886 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid aerosol device with clinical counseling
Number of subjects: 0
Study 8261886 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine particle ascorbic acid device
Number of subjects: 0
Study 8261886 — intervention group
Group type: COMPARATOR
Intervention: Coarse particle ascorbic acid device
Number of subjects: 0
Study 2579868 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal mixed nutrients, proteins, and lipids
Number of subjects: 6
Study 2579868 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal lipids
Number of subjects: 6
Study 2579868 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal sugars
Number of subjects: 6
Study 2579868 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal mixed meal
Number of subjects: 6
Study 30837195 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT plus PT (PT‐BoNT arm)
Number of subjects: 26
Study 30837195 — intervention group
Group type: COMPARATOR
Intervention: BoNT alone (BoNT arm)
Number of subjects: 26
Study 30388182 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior Changing Intervention (BCI)
Number of subjects: 2140
Study 30388182 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge related module
Number of subjects: 2140
Study 30388182 — intervention group
Group type: EXPERIMENTAL
Intervention: Quit preparation module
Number of subjects: 2140
Study 27468229 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-managed clinic (PMC)
Number of subjects: 244
Study 23271039 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative home exercise program (6-week duration)
Number of subjects: 122
Study 23271039 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative exercise program)
Number of subjects: 122
Study 22803422 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint heat-sensitization moxibustion (Group A), once daily for 4 weeks
Number of subjects: 60
Study 22803422 — intervention group
Group type: COMPARATOR
Intervention: Changtai Oral Liquid (Group B), 10 mL three times daily for 4 weeks
Number of subjects: 60
Study 22803422 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint heat-sensitization moxibustion (Group A)
Number of subjects: 60
Study 22803422 — intervention group
Group type: COMPARATOR
Intervention: Changtai Oral Liquid (Group B)
Number of subjects: 60
Study 22803422 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 60
Study 20234040 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care (n=66)
Number of subjects: 134
Study 20234040 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=68)
Number of subjects: 134
Study 17405808 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi (TC)
Number of subjects: 269
Study 17405808 — intervention group
Group type: COMPARATOR
Intervention: Wellness education (WE)
Number of subjects: 269
Study 15825977 — intervention group
Group type: EXPERIMENTAL
Intervention: Translated consent form developed by Navajo interpreters and a language consultant; duration of use: four months.
Number of subjects: 0
Study 15825977 — intervention group
Group type: COMPARATOR
Intervention: Standard research consent form (not translated); duration of use: not specified.
Number of subjects: 0
Study 12121581 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry tablets (taken twice daily)
Number of subjects: 150
Study 12121581 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice (250 ml three times daily)
Number of subjects: 150
Study 12121581 — intervention group
Group type: COMPARATOR
Intervention: Placebo (juice + tablets)
Number of subjects: 150
Study 12121581 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry tablets
Number of subjects: 150
Study 12121581 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice
Number of subjects: 150
Study 12121581 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry tablets vs. cranberry juice
Number of subjects: 150
Study 12121581 — intervention group
Group type: EXPERIMENTAL
Intervention: Both cranberry juice and cranberry tablets
Number of subjects: 150
Study 9707877 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (0.25 mg/kg)
Number of subjects: 76
Study 9707877 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 76
Study 7899366 — intervention group
Group type: EXPERIMENTAL
Intervention: Pefloxacin 400 mg once-a-week (group A: n = 185)
Number of subjects: 361
Study 7899366 — intervention group
Group type: COMPARATOR
Intervention: Pefloxacin 400 mg once-a-month (group B: n = 176)
Number of subjects: 361
Study 7899366 — intervention group
Group type: EXPERIMENTAL
Intervention: Pefloxacin 400 mg once-a-week (group A)
Number of subjects: 361
Study 7899366 — intervention group
Group type: COMPARATOR
Intervention: Pefloxacin 400 mg once-a-month (group B)
Number of subjects: 361
Study 2526830 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intravenous and intracoronary streptokinase without immediate coronary angioplasty (Group I)
Number of subjects: 206
Study 2526830 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intravenous and intracoronary streptokinase with immediate coronary angioplasty (Group II)
Number of subjects: 206
Study 20918 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam (20 mg)
Number of subjects: 10
Study 20918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31033995 — intervention group
Group type: COMPARATOR
Intervention: Psychological symptoms
Number of subjects: 351
Study 31033995 — intervention group
Group type: COMPARATOR
Intervention: Anxiety symptoms
Number of subjects: 351
Study 31033995 — intervention group
Group type: COMPARATOR
Intervention: Vasomotor symptoms
Number of subjects: 351
Study 31033995 — intervention group
Group type: COMPARATOR
Intervention: Depression symptoms
Number of subjects: 351
Study 31033995 — intervention group
Group type: COMPARATOR
Intervention: Somatic symptoms
Number of subjects: 351
Study 31033995 — intervention group
Group type: COMPARATOR
Intervention: Loss of interest in sex symptoms
Number of subjects: 351
Study 31033995 — intervention group
Group type: COMPARATOR
Intervention: Menopausal symptoms
Number of subjects: 351
Study 28501062 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic Propolis as an adjuvant to nonsurgical periodontal treatment
Number of subjects: 0
Study 28501062 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical periodontal treatment
Number of subjects: 0
Study 26153173 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg propranolol, 2 hours before surgery
Number of subjects: 122
Study 26153173 — intervention group
Group type: COMPARATOR
Intervention: Combination of 15 mg ketamine and 50 µg fentanyl, 5 min before surgery
Number of subjects: 122
Study 23569136 — intervention group
Group type: EXPERIMENTAL
Intervention: QuickOpt® optimization (n = 20)
Number of subjects: 44
Study 23569136 — intervention group
Group type: COMPARATOR
Intervention: Echocardiography optimization (n = 24)
Number of subjects: 44
Study 20980491 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine omega-3 fatty acids intake
Number of subjects: 36328
Study 20980491 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish intake
Number of subjects: 36328
Study 19349560 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention
Number of subjects: 54
Study 19349560 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study 16368752 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment (2 IU/m2)
Number of subjects: 23
Study 16368752 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 23
Study 15217320 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 152438
Study 15217320 — intervention group
Group type: COMPARATOR
Intervention: No BCG vaccination (control)
Number of subjects: 152438
Study 11080323 — intervention group
Group type: EXPERIMENTAL
Intervention: AeroVent
Number of subjects: 3
Study 11080323 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiVent
Number of subjects: 3
Study 11080323 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE
Number of subjects: 3
Study 11080323 — intervention group
Group type: COMPARATOR
Intervention: Heated-wire ventilator circuit
Number of subjects: 3
Study 9032099 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone 800 mg q.d.
Number of subjects: 154
Study 9032099 — intervention group
Group type: COMPARATOR
Intervention: Glyburide titrated to achieve glycemic control
Number of subjects: 154
Study 8510088 — intervention group
Group type: EXPERIMENTAL
Intervention: rilmenidine (RIL)
Number of subjects: 20
Study 8510088 — intervention group
Group type: COMPARATOR
Intervention: hydrochlorothiazide (HCT)
Number of subjects: 20
Study 2952140 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography (CT)
Number of subjects: 177
Study 2952140 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-guided needle biopsy
Number of subjects: 177
Study 31398258 — intervention group
Group type: EXPERIMENTAL
Intervention: Online decision aid (DA) in addition to standard counselling
Number of subjects: 59
Study 31398258 — intervention group
Group type: COMPARATOR
Intervention: Standard counselling only
Number of subjects: 59
Study 29284735 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact Aspiration (CA)
Number of subjects: 79
Study 29284735 — intervention group
Group type: COMPARATOR
Intervention: Stent Retriever (SR)
Number of subjects: 79
Study 26966970 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive patient education
Number of subjects: 216
Study 26966970 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 216
Study 25220724 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune investigation including complement function, immunoglobulins with subclasses and cellular immunity.
Number of subjects: 109
Study 25220724 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune investigation in children with severe rAOM.
Number of subjects: 109
Study 25220724 — intervention group
Group type: COMPARATOR
Intervention: Immune investigation in children without severe rAOM.
Number of subjects: 109
Study 22711185 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g of EMLA
Number of subjects: 90
Study 22711185 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg diclofenac suppository
Number of subjects: 90
Study 22711185 — intervention group
Group type: COMPARATOR
Intervention: 5 g of petrolatum ointment
Number of subjects: 90
Study 20492038 — intervention group
Group type: EXPERIMENTAL
Intervention: Music programme during lunchtime
Number of subjects: 41
Study 17276176 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 100
Study 17276176 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 100
Study 15030456 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir 3 g daily from engraftment to day 84
Number of subjects: 58
Study 15030456 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ganciclovir 5 mg/kg three times weekly from engraftment to day 84
Number of subjects: 58
Study 15030456 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ganciclovir
Number of subjects: 58
Study 15030456 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir
Number of subjects: 58
Study 11473677 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose inhaled corticosteroids (CS)
Number of subjects: 58
Study 9433395 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary or recombinant human follicle stimulating hormone (FSH) treatment
Number of subjects: 0
Study 8495690 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich diet (CHO) for 3 days
Number of subjects: 6
Study 8495690 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate deficient, protein/fat rich diet (F) for 3 days
Number of subjects: 6
Study 8495690 — intervention group
Group type: COMPARATOR
Intervention: Normal unrestricted diet of western type (N)
Number of subjects: 6
Study 8495690 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergometer cycle endurance test
Number of subjects: 6
Study 3325531 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 20
Study 3325531 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 20
Study 29985230 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 93
Study 29985230 — intervention group
Group type: COMPARATOR
Intervention: No tranexamic acid (No‐TXA)
Number of subjects: 93
Study 26590950 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release-plus-immediate-release bilayer tablet (Test)
Number of subjects: 16
Study 26590950 — intervention group
Group type: COMPARATOR
Intervention: Gastro-resistant delayed-release tablet (Reference)
Number of subjects: 16
Study 24980811 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin-based triple therapy (MML): moxifloxacin 400 mg/day, metronidazole 500 mg b.i.d., lansoprazole 30 mg b.i.d. for 10 days
Number of subjects: 0
Study 24980811 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment (AL-CML): amoxicillin 1 g b.i.d. and lansoprazole 30 mg b.i.d. for the first 5 days, followed by clarithromycin 500 mg b.i.d., metronidazole 500 mg b.i.d. and lansoprazole 30 mg b.i.d. for the second 5 days
Number of subjects: 0
Study 24980811 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment (CAL): amoxicillin 1 g b.i.d., clarithromycin 500 mg b.i.d. and lansoprazole 30 mg b.i.d. for 14 days
Number of subjects: 0
Study 21999231 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO‐rFVIIa (90 μg/kg for healthy subjects; 270 μg/kg for patients)
Number of subjects: 2
Study 21999231 — intervention group
Group type: COMPARATOR
Intervention: BHK‐rFVIIa (90 μg/kg for healthy subjects; 270 μg/kg for patients)
Number of subjects: 2
Study 20233687 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated competition
Number of subjects: 14
Study 20233687 — intervention group
Group type: COMPARATOR
Intervention: Control laboratory conditions (non-competition)
Number of subjects: 14
Study 18672762 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound Paeonol Dripping Pill (CPDP)
Number of subjects: 90
Study 18672762 — intervention group
Group type: COMPARATOR
Intervention: Conventional Western therapy (Group A)
Number of subjects: 90
Study 18672762 — intervention group
Group type: COMPARATOR
Intervention: Tongxinluo (Group C)
Number of subjects: 90
Study 16896051 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin/mineral combination (factor A: retinol and zinc; factor B: riboflavin and niacin; factor C: ascorbic acid and molybdenum; factor D: beta-carotene, alpha-tocopherol, and selenium)
Number of subjects: 29584
Study 16896051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29584
Study 12795457 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole + Clarithromycin (OC) for 2 weeks
Number of subjects: 240
Study 12795457 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole + Amoxicillin + Clarithromycin (OAC-L) for 1 week
Number of subjects: 240
Study 12795457 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole + Amoxicillin + Clarithromycin (OAC-H) for 1 week
Number of subjects: 240
Study 12795457 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole + Metronidazole + Clarithromycin (OMC) for 1 week
Number of subjects: 240
Study 11035891 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol administered 1 day after mifepristone
Number of subjects: 2295
Study 11035891 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol administered 2 days after mifepristone
Number of subjects: 2295
Study 11035891 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol administered 3 days after mifepristone
Number of subjects: 2295
Study 11035891 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects (cramping and nausea)
Number of subjects: 2295
Study 11035891 — intervention group
Group type: EXPERIMENTAL
Intervention: Unexpected or serious adverse events
Number of subjects: 2295
Study 11035891 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptability of the procedure
Number of subjects: 2295
Study 8781154 — intervention group
Group type: EXPERIMENTAL
Intervention: Oblique path (n = 32)
Number of subjects: 61
Study 8781154 — intervention group
Group type: COMPARATOR
Intervention: Nearly right angle path (n = 30)
Number of subjects: 61
Study 1310096 — intervention group
Group type: EXPERIMENTAL
Intervention: Peridex (chlorhexidine)
Number of subjects: 71
Study 1310096 — intervention group
Group type: EXPERIMENTAL
Intervention: Perimed (povidone iodine and hydrogen peroxide)
Number of subjects: 71
Study 1310096 — intervention group
Group type: COMPARATOR
Intervention: Listerine Antiseptic (thymol)
Number of subjects: 71
Study 1310096 — intervention group
Group type: COMPARATOR
Intervention: Placebo (water)
Number of subjects: 71
Study 6422811 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea patients
Number of subjects: 5
Study 6422811 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 5
Study 6422811 — intervention group
Group type: EXPERIMENTAL
Intervention: Load detection threshold
Number of subjects: 5
Study 30737891 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 884
Study 30737891 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 884
Study 29414377 — intervention group
Group type: EXPERIMENTAL
Intervention: Light (illuminated LED fixture)
Number of subjects: 15
Study 29414377 — intervention group
Group type: COMPARATOR
Intervention: Dark (unilluminated LED fixture)
Number of subjects: 15
Study 29414377 — intervention group
Group type: COMPARATOR
Intervention: Baseline (no lighting fixture)
Number of subjects: 15
Study 26679443 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message notification within 24 hours of receipt of abnormal mammogram
Number of subjects: 29
Study 26679443 — intervention group
Group type: COMPARATOR
Intervention: Delayed text message notification (4 weeks later)
Number of subjects: 29
Study 24464788 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 6797
Study 24464788 — intervention group
Group type: COMPARATOR
Intervention: Control group (no enalapril)
Number of subjects: 6797
Study 23044035 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week dairy intake intervention via electronic mail
Number of subjects: 211
Study 23044035 — intervention group
Group type: COMPARATOR
Intervention: Stress management intervention via electronic mail
Number of subjects: 211
Study 19156626 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (alpha-glucosidase inhibitor)
Number of subjects: 1368
Study 19156626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1368
Study 17194889 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 0
Study 17194889 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 0
Study 17194889 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 0
Study 17194889 — intervention group
Group type: COMPARATOR
Intervention: PPARalpha-deficient mice and adipocytes
Number of subjects: 0
Study 14668187 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifugal pump
Number of subjects: 34
Study 14668187 — intervention group
Group type: COMPARATOR
Intervention: Roller pump
Number of subjects: 34
Study 11200923 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodialysis
Number of subjects: 22
Study 8776746 — intervention group
Group type: EXPERIMENTAL
Intervention: Brofaromine (CGP 11,305 A), a selective and reversible MAO A inhibitor
Number of subjects: 0
Study 8776746 — intervention group
Group type: COMPARATOR
Intervention: Nonparametric Wilcoxon signed-rank test
Number of subjects: 0
Study 8776746 — intervention group
Group type: COMPARATOR
Intervention: ANOVA of transformed data
Number of subjects: 0
Study 1470044 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 beta‐oestradiol 10 micrograms
Number of subjects: 24
Study 1470044 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 beta‐oestradiol 25 micrograms
Number of subjects: 24
Study 6376292 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripotassium dicitrato bismuthate (TDB) tablet four times a day
Number of subjects: 25
Study 6376292 — intervention group
Group type: COMPARATOR
Intervention: High dose cimetidine (1.6 g daily)
Number of subjects: 25
Study 6376292 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripotassium dicitrato bismuthate (TDB) after crossover
Number of subjects: 25